Booth 5641
Rousselot, Darling Ingredients’ collagen and gelatin brand, will reveal the results of its first clinical study on Nextida GC, a composition of collagen peptides formulated to support glucose balance.
The study showed that both five and 10 grams of the ingredient significantly reduced post-meal spikes in blood glucose in healthy individuals when taken 30 minutes before a meal, by an average of 42%.
“We’re immensely excited to take our new step toward decoding the collagen molecule with the release of this first study,” said Jeroen Colpaert, executive vice president, Rousselot. “With new science supporting our ingredient’s potential for post-meal glucose metabolism in healthy individuals, we are continuing our commitment to offering the health and wellness industry evidence-based solutions that expand what we know about collagen.”
Rousselot is the official glucose management sponsor of SupplySide West, and will deliver two expert presentations shedding light on the topic. Janne Prawitt, PhD, scientific director of health and nutrition at Rousselot, and Mariette Abrahams, PhD, MBA, CEO and founder at Qina, will discuss Nextida GC and consumer interest in metabolic health on Oct. 30 from 12:00-1:00 p.m. at the lower level South Pacific Ballroom D. On Oct. 31, from 11:00-11:20 a.m., Prawitt will provide insights into Nextida GC’s first clinical trial.
Show attendees can also learn more at Rousselot’s booth about recently published, peer-reviewed clinical studies on the company’s flagship collagen peptide ingredient Peptan. One study highlights the ingredient’s effects on skin beauty markers, while another demonstrates its effective absorption.
SupplySide Global
Rousselot Launches Nextida GC Ingredient to Target Post-Meal Glucose Spikes
The company will reveal the results of its first clinical study at SupplySide West
